Table 5 Interaction between pSS and cDDD group in bisphosphonate and non-bisphosphonate users.

From: Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw

 

Case 1: bisphosphonate users

Case 2: non-bisphosphonate users

ADJ. HR

95% CI

ADJ. HR

95% CI

pSS

 No (Ref.)

1.000

 

1.000

 

 Yes

2.509*

(1.141–5.515)

0.549

(0.145–2.076)

CDDD group

 < 224(Ref.)

1.000

 

1.000

 

 ≥ 224

0.705

(0.385–1.292)

0.534

(0.262–1.089)

Interaction

 pSS*cDDD group

0.701

(0.254–1.932)

1.117

(0.160–7.782)

  1. (1) *0.01 ≤ p < 0.05, **0.0001 ≤ p < 0.01, ***p < 0.0001. (2) ‡ADJ. HR was adjusted by sex, comorbidities, and age at the initiation of bisphosphonate use.
  2. pSS primary Sjogren syndrome, cDDD cumulative dose with defined daily dose, 95% CI 95% confidence interval, ADJ. HR adjusted hazard ratio, Ref reference.
Back to article page